New Hypofractionation Radiation Strategies for Glioblastoma

Melissa Azoulay, Jennifer Shah, Erqi Pollom, Scott G. Soltys

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Purpose of Review: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Recent Findings: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Summary: Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.

Original languageEnglish (US)
Article number58
JournalCurrent oncology reports
Issue number9
StatePublished - Sep 1 2017


  • Adverse radiation effect
  • Glioblastoma
  • Hypofractionation
  • Immunotherapy
  • Radiation
  • Radionecrosis
  • Radiotherapy
  • Stereotactic radiosurgery
  • Temozolomide

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New Hypofractionation Radiation Strategies for Glioblastoma'. Together they form a unique fingerprint.

Cite this